Advancing Live Biotherapeutics: The Butyricicoccus porcorum Advantage
The gut microbiome is the next frontier in human health, and Live Biotherapeutic Products (LBPs) represent a paradigm shift in treating complex diseases. At the forefront of this innovation lies the fascinating bacterium, Butyricicoccus porcorum. As a leading Contract Research Organization (CRO) specializing in preclinical LBP research, Creative Biolabs recognizes the immense therapeutic potential of this potent butyrate producer. Our dedicated service platform is designed to rapidly and rigorously de-risk your B. porcorum-based therapeutic candidates, transforming promising microbial science into viable clinical strategies. Partner with us to accelerate your journey from bench to bedside and unlock the full potential of this next-generation probiotic for intestinal health and beyond.
Overview: What is Butyricicoccus porcorum?
Butyricicoccus porcorum is an obligate anaerobic, Gram-positive, coccoid-shaped bacterium originally isolated from the swine intestinal tract. Critically, it belongs to the Clostridial cluster IV/XIVa, a group renowned for its efficient production of Short-Chain Fatty Acids (SCFAs), particularly butyrate. Butyrate is a cornerstone of intestinal health, serving as the primary energy source for colonocytes (colon lining cells) and playing a crucial role in maintaining epithelial barrier integrity and regulating host immune responses. A novel strain of B. porcorum has recently been isolated from the human gut microbiota, highlighting its relevance as a potential Next-Generation Probiotic (NGP). This human isolate exhibits unique metabolic capabilities, including a capacity for one-carbon metabolism, making it a compelling candidate for LBP development.
Our Preclinical Service Offerings
As a specialized CRO in Live Biotherapeutics, we offer an integrated suite of preclinical services tailored to the unique challenges of developing B. porcorum-based LBPs. Our expertise spans strain characterization to IND-enabling safety studies.
Butyrate Production Profiling: Quantitative analysis of butyrate and other SCFA production (acetate, propionate) under various in vitro conditions (e.g., substrate availability, pH, oxygen).
Genomic Sequencing & Analysis: Complete genome sequencing, annotation, and comparative genomics (e.g., comparison with B. pullicaecorum). Assessment for virulence factors and antibiotic resistance genes.
Carbohydrate Utilization Analysis: Detailed fermentative profiling on simple and complex carbohydrates to understand metabolic preferences and host/dietary dependencies.
Stability & Viability Assays: Testing of survival under simulated GI tract conditions (acid/bile tolerance) and shelf-life stability in various formulations.
We provide robust animal models that accurately reflect the human disease pathology targeted by B. porcorum.
IBD/Colitis Models: Utilize models such as DSS- or TNBS-induced colitis in mice/rats to assess B. porcorum's ability to mitigate inflammation, reduce lesion scores, and restore gut barrier function.
Immune System Modulation Models: Assess immune cell profiles (Tregs, Th17, DCs) in the Peyer's patches, Mesenteric Lymph Nodes, and colon via flow cytometry and RNA sequencing after LBP administration.
Gut Microbiota Analysis: Comprehensive 16S rRNA gene sequencing and whole-metagenome shotgun sequencing to track B. porcorum colonization, persistence, and its impact on the overall microbial community structure.
Metabolomics: Targeted and untargeted metabolomic profiling of fecal, serum, and tissue samples to quantify SCFAs and other microbial-host metabolites in vivo.
Safety and Toxicology
Acute and Repeated-Dose Oral Toxicity Studies: Standardized studies in relevant preclinical species to determine the No-Observed-Adverse-Effect-Level (NOAEL).
Safety Pharmacology: Assessment of effects on vital organ systems (Cardiovascular, Respiratory, Central Nervous System).
Toxicokinetics/Shedding Studies: Monitoring the presence, persistence, and clearance of the LBP in the host and environment.
Preclinical Product Offerings
To support your B. porcorum research, we offer high-quality, research-grade microbial products.
Research-Grade Strain: Access to well-characterized B. porcorum strains.
This product contains high-quality, intact genomic DNA isolated from Butyricicoccus pullicaecorum Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Custom Fermentation & Production: Small-scale production of customized, concentrated B. porcorum biomass or culture supernatant for preclinical animal studies. We ensure high viability and purity under strict anaerobic conditions.
Research Applications in Disease Treatment
A reduced abundance of the Butyricicoccus genus has been strongly correlated with various human intestinal disorders, most notably Inflammatory Bowel Diseases (IBD), such as Crohn's disease and ulcerative colitis. This deficiency underscores the therapeutic rationale for using B. porcorum to restore microbial balance and buttress intestinal function. The therapeutic focus for B. porcorum centers on its role as a powerful intestinal homeostasis modulator and butyrate donor. Preclinical research has illuminated several exciting disease targets and mechanisms of action.
Inflammatory Bowel Diseases (IBD) and Colitis: As a potent butyrate producer, B. porcorum directly supports the gut epithelium. Butyrate is a well-established anti-inflammatory molecule that can strengthen the gut barrier and modulate the immune system.
Immune Modulation and Autoimmunity: Dendritic cell (DC) activation and T-cell differentiation.
Metabolic and Endocrine Disorders: B. porcorum has been shown to restrict the biosynthesis of cholesterols and calibrate carbohydrate metabolic function in the gut. Altering the gut microbiome composition and metabolic signaling offers a novel approach to addressing conditions linked to metabolic dysfunction.
Our Competitive Advantages
Deep LBP Expertise
We are a CRO exclusively focused on Live Biotherapeutics, providing domain-specific knowledge that general CROs lack.
Advanced Anaerobic Capabilities
State-of-the-art anaerobic chambers and continuous culture systems (like chemostats) are optimized for the challenging growth requirements of strict anaerobes like B. porcorum.
Integrated Multi-Omics Platform
Seamless integration of genomics, transcriptomics (RNA-seq of host tissue), and metabolomics for a comprehensive mechanistic understanding, moving beyond simple colonization checks.
The age of the microbiome therapeutic is here. The potential of Butyricicoccus porcorum to safely and effectively treat chronic, debilitating diseases by restoring a fundamental process of intestinal health is unparalleled. Creative Biolabs is not just a service provider; we are your strategic partner in pioneering the next generation of medicine.
Why is butyrate production so critical for an LBP?
Butyrate is the key mediator of gut health. It is the primary fuel for colonocytes, maintains the epithelial barrier (the first line of defense), and possesses potent anti-inflammatory and immunomodulatory properties. An effective butyrate producer like B. porcorum directly addresses the SCFA deficiency often seen in inflammatory and metabolic diseases.
What is the main difference between B. porcorum and B. pullicaecorum?
Both are potent butyrate producers, but they are distinct species with different genomic and functional profiles. B. porcorum (especially novel human isolates) has shown unique metabolic and immune-modulating characteristics, such as restricting cholesterol biosynthesis and specific immune programming, suggesting a distinct mechanism of action worthy of separate investigation.
What animal models are most relevant for IBD studies with this strain?
The DSS-induced colitis model in mice is the industry standard for acute inflammation and is highly relevant for testing the epithelial protective and anti-inflammatory effects of B. porcorum. We can also employ chronic models or germ-free mice colonized with a defined consortium for mechanistic studies.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
